EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Bacterial Vaginosis - Pipeline Review, H1 2017

  • ID: 4091070
  • Report
  • February 2017
  • 47 pages
  • Global Markets Direct
1 of 4
Bacterial Vaginosis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Bacterial Vaginosis - Overview

Bacterial Vaginosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacterial Vaginosis - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Vaginosis - Companies Involved in Therapeutics Development

Evofem Inc

Osel Inc

Starpharma Holdings Ltd

Symbiomix Therapeutics LLC

Bacterial Vaginosis - Drug Profiles

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzoyl peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LACTIN-V - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

secnidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

subtilosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Vaginosis - Dormant Projects

Bacterial Vaginosis - Discontinued Products

Bacterial Vaginosis - Product Development Milestones

Featured News & Press Releases

Jan 19, 2017: Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec for the Treatment of BV

Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA

Nov 07, 2016: Symbiomix Therapeutics to Present Data on Solosec (Secnidazole) Oral Granules at 2016 AAPS Annual Meeting and Exposition

Oct 25, 2016: Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference

Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program

Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH

Aug 17, 2016: Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec Following Presentation of Results from Second Pivotal Trial at IDSOG

Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health

May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing

May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis

Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis

Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora

Oct 14, 2015: Additional US Patent granted for VivaGel BV

Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV

Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Bacterial Vaginosis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Bacterial Vaginosis - Pipeline by Evofem Inc, H1

Bacterial Vaginosis - Pipeline by Osel Inc, H1

Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H1

Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics LLC, H1

Bacterial Vaginosis - Dormant Projects, H1

Bacterial Vaginosis - Discontinued Products, H1

List of Figures:

Number of Products under Development for Bacterial Vaginosis, H1

Number of Products under Development by Companies, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Evofem Inc
  • Osel Inc
  • Starpharma Holdings Ltd
  • Symbiomix Therapeutics LLC
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll